• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial
Dextromethorphan (DM)/quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based upon efficacy and safety trials in patients with PBA secondary to amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PBA treatment in patients with stroke, dementia or traumatic brain injury.
Source: PM and R - July 2, 2018 Category: Rehabilitation Authors: Richard D. Zorowitz, David N. Alexander, Andrea E. Formella, Fred Ledon, Charles Davis, Joao Siffert Source Type: research

Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study
Dextromethorphan 20mg /quinidine 10mg (DM/Q) was approved to treat pseudobulbar affect (PBA) based upon phase 3 trials conducted in participants with amyotrophic lateral sclerosis or multiple sclerosis. PRISM II evaluated DM/Q effectiveness, safety and tolerability for PBA following stroke, dementia or traumatic brain injury (TBI). Objective. To report results from the TBI cohort of PRISM II, including a TBI-specific functional scale. Design. Open-label trial evaluating twice daily DM/Q over 90 days.
Source: PM and R - February 22, 2018 Category: Rehabilitation Authors: Flora M. Hammond, William Sauve, Fred Ledon, Charles Davis, Andrea E. Formella Source Type: research

Poster 298: Lewy Body Dementia in a Patient with Confounding Post-Stroke Symptoms: A Case Report
Katie Hatt, DO: I Have No Relevant Financial Relationships To Disclose
Source: PM and R - September 1, 2017 Category: Rehabilitation Authors: Katie Hatt, Nicholas C. Kinback, Ning Cao Source Type: research